F Manganelli1, C Pisciotta2, M M Reilly3, S Tozza2, A Schenone4, G M Fabrizi5, T Cavallaro6, G Vita7, L Padua8,9, F Gemignani10, M Laurà3, R A C Hughes3, A Solari11, D Pareyson11, L Santoro2. 1. Department of Neurosciences, Reproductive Sciences and Odontostomatology, University Federico II of Naples, Naples, Italy. fioremanganelli@gmail.com. 2. Department of Neurosciences, Reproductive Sciences and Odontostomatology, University Federico II of Naples, Naples, Italy. 3. MRC Centre for Neuromuscular Diseases, Institute of Neurology, University College London, London, UK. 4. Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics and Maternal Infantile Sciences, University of Genoa, Genoa, Italy. 5. Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy. 6. Department of Neuroscience, AOUI, Verona, Italy. 7. Department of Clinical and Experimental Medicine, School of Neurosciences, University of Messina, Messina, Italy. 8. Department of Geriatrics, Neurosciences and Orthopaedics, Università Cattolica del Sacro Cuore, Rome, Italy. 9. Don Carlo Gnocchi Foundation, Milan, Italy. 10. Department of Neurosciences, University of Parma, Parma, Italy. 11. Carlo Besta Neurological Institute, IRCCS Foundation, Milan, Italy.
Abstract
BACKGROUND AND PURPOSE: Charcot-Marie-Tooth disease (CMT) type 1A is characterized by uniformly reduced nerve conduction velocity (NCV) that is fully penetrant since the first years of life, remains fairly stable through the life and does not correlate with disability whereas compound muscular action potential (CMAP) amplitude does. The aim of the present study was to analyze the large amount of electrophysiological data collected in the ascorbic acid trial in Italy and the UK (CMT-TRIAAL/CMT-TRAUK) and to use these data to gain insights into the pathophysiology of NCV in CMT1A. METHODS: Baseline electrophysiological data from 271 patients were analysed. Electrophysiological recordings were taken from the motor ulnar, median and peroneal nerves and the sensory ulnar nerve. Distal motor latency (DML), motor (MNCV) and sensory (SNCV) nerve conduction velocity, and amplitudes of CMAPs and sensory action potentials were assessed. Electrophysiological findings were correlated with age of patients at examination and the Charcot-Marie-Tooth Examination Score (CMTES). RESULTS: NCV was markedly and uniformly reduced. CMAP amplitudes were overall reduced but more severely in lower limbs. DML decreased and MNCV and SNCV increased with age of the patients, whereas CMAP amplitudes worsened with age and also correlated with CMTES. CONCLUSIONS: This is the largest sample of electrophysiological data obtained so far from CMT1A patients. Axonal degeneration as assessed by means of CMAP amplitude reflected clinical impairment and was consistent with a slowly progressive length-dependent neuropathy. All patients typically had markedly slowed NCV that did, however, slightly increase with age of the patients. The improvement of NCV might depend on myelin thickness remodelling that occurs during the adult life of CMT1A patients.
BACKGROUND AND PURPOSE:Charcot-Marie-Tooth disease (CMT) type 1A is characterized by uniformly reduced nerve conduction velocity (NCV) that is fully penetrant since the first years of life, remains fairly stable through the life and does not correlate with disability whereas compound muscular action potential (CMAP) amplitude does. The aim of the present study was to analyze the large amount of electrophysiological data collected in the ascorbic acid trial in Italy and the UK (CMT-TRIAAL/CMT-TRAUK) and to use these data to gain insights into the pathophysiology of NCV in CMT1A. METHODS: Baseline electrophysiological data from 271 patients were analysed. Electrophysiological recordings were taken from the motor ulnar, median and peroneal nerves and the sensory ulnar nerve. Distal motor latency (DML), motor (MNCV) and sensory (SNCV) nerve conduction velocity, and amplitudes of CMAPs and sensory action potentials were assessed. Electrophysiological findings were correlated with age of patients at examination and the Charcot-Marie-Tooth Examination Score (CMTES). RESULTS: NCV was markedly and uniformly reduced. CMAP amplitudes were overall reduced but more severely in lower limbs. DML decreased and MNCV and SNCV increased with age of the patients, whereas CMAP amplitudes worsened with age and also correlated with CMTES. CONCLUSIONS: This is the largest sample of electrophysiological data obtained so far from CMT1Apatients. Axonal degeneration as assessed by means of CMAP amplitude reflected clinical impairment and was consistent with a slowly progressive length-dependent neuropathy. All patients typically had markedly slowed NCV that did, however, slightly increase with age of the patients. The improvement of NCV might depend on myelin thickness remodelling that occurs during the adult life of CMT1Apatients.
Authors: Robert Fledrich; Ruth M Stassart; Axel Klink; Lennart M Rasch; Thomas Prukop; Lauren Haag; Dirk Czesnik; Theresa Kungl; Tamer A M Abdelaal; Naureen Keric; Christine Stadelmann; Wolfgang Brück; Klaus-Armin Nave; Michael W Sereda Journal: Nat Med Date: 2014-08-24 Impact factor: 53.440
Authors: Camiel Verhamme; Rosalind H M King; Anneloor L M A ten Asbroek; John R Muddle; Michelle Nourallah; Ruud Wolterman; Frank Baas; Ivo N van Schaik Journal: J Neuropathol Exp Neurol Date: 2011-05 Impact factor: 3.685
Authors: P K Thomas; W Marques; M B Davis; M G Sweeney; R H King; J L Bradley; J R Muddle; J Tyson; S Malcolm; A E Harding Journal: Brain Date: 1997-03 Impact factor: 13.501
Authors: K M Krajewski; R A Lewis; D R Fuerst; C Turansky; S R Hinderer; J Garbern; J Kamholz; M E Shy Journal: Brain Date: 2000-07 Impact factor: 13.501
Authors: Joshua Burns; Robert A Ouvrier; Eppie M Yiu; Pathma D Joseph; Andrew J Kornberg; Michael C Fahey; Monique M Ryan Journal: Lancet Neurol Date: 2009-05-06 Impact factor: 44.182
Authors: M E Shy; L Chen; E R Swan; R Taube; K M Krajewski; D Herrmann; R A Lewis; M P McDermott Journal: Neurology Date: 2008-01-29 Impact factor: 9.910
Authors: Galin V Michailov; Michael W Sereda; Bastian G Brinkmann; Tobias M Fischer; Bernhard Haug; Carmen Birchmeier; Lorna Role; Cary Lai; Markus H Schwab; Klaus-Armin Nave Journal: Science Date: 2004-03-25 Impact factor: 47.728
Authors: A A Gabreëls-Festen; P A Bolhuis; J E Hoogendijk; L J Valentijn; E J Eshuis; F J Gabreëls Journal: Acta Neuropathol Date: 1995 Impact factor: 17.088
Authors: Marina Stavrou; Alexia Kagiava; Sarah G Choudury; Matthew J Jennings; Lindsay M Wallace; Allison M Fowler; Amanda Heslegrave; Jan Richter; Christina Tryfonos; Christina Christodoulou; Henrik Zetterberg; Rita Horvath; Scott Q Harper; Kleopas A Kleopa Journal: J Clin Invest Date: 2022-07-01 Impact factor: 19.456
Authors: Hongge Wang; Matthew Davison; Kathryn Wang; Tai-He Xia; Katherine M Call; Jun Luo; Xingyao Wu; Riccardo Zuccarino; Alexa Bacha; Yunhong Bai; Laurie Gutmann; Shawna M E Feely; Tiffany Grider; Alexander M Rossor; Mary M Reilly; Michael E Shy; John Svaren Journal: Neurology Date: 2021-05-24 Impact factor: 11.800
Authors: Aurora Messina; Natasha Van Zyl; Michael Weymouth; Stephen Flood; Andrew Nunn; Catherine Cooper; Jodie Hahn; Mary P Galea Journal: Brain Sci Date: 2016-09-27